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Anatomical Information Is Incremental to Clinical Risk Prediction
Objectives We sought to determine the incremental prognostic value of 64 multi-slice coronary computed tomography an-
giography (CCTA) in coronary artery bypass graft (CABG) patients.
Background Prognostication in CABG patients can be difficult. Anatomical assessment of native coronary artery disease and
graft patency might provide useful information, but the utility of CCTA in the assessment of CABG patients is
unknown.
Methods Six hundred fifty-seven CABG patients with all-cause mortality follow-up were identified from a multicenter CCTA
registry, of 10,628 patients from 5 CCTA centers. Clinical risk was profiled with modified logistic and additive
EuroSCOREs (European Systems for Cardiac Operative Risk Evaluations). The CCTA defined coronary anatomy.
Patients were classified by unprotected coronary territory (UCT) or a summary of native vessel disease and graft
patency: the coronary artery protection score (CAPS).
Results Forty-four deaths occurred during a mean follow-up of 20 months. Left ventricular ejection fraction, creatinine,
age, severity of native vessel disease, UCT, CAPS, and EuroSCOREs were univariate predictors of mortality (p 
0.001). In multivariate analysis with additive EuroSCORE, UCT (p  0.004) and CAPS were predictive of events
(p  0.001). In comparison with additive EuroSCORE, CAPS score was associated with a 27% net reclassification
index.
Conclusions Coronary computed tomography angiography provides incremental anatomical data to clinical risk assessment
to help determine the prognosis of patients after CABG. The CAPS evaluation with CCTA might help identify
those patients at highest risk. (J Am Coll Cardiol 2011;58:2389–95) © 2011 by the American College of
Cardiology FoundationCoronary computed tomography angiography (CCTA) is
an emerging technique, with the potential ability to risk-
stratify coronary artery bypass (CABG) patients on the basis
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accepted August 9, 2011.of native vessel anatomy and graft patency (1–4). The utility
of risk stratification of CABG patients on the basis of
anatomy has been shown with invasive angiography but has
not been well-studied with CCTA (5). A noninvasive
anatomical test might be desirable, acknowledging that
complications from invasive coronary angiography are
higher in the CABG population (6).
There are limited data demonstrating the prognostic
utility of CCTA in CABG patients. With a multicenter
CCTA registry, we sought to evaluate the incremental
prognostic value of CCTA to predict all-cause death in
CABG patients.
Methods
From February 2004 to June 2010, 10,628 consecutive
patients underwent CCTA at 5 centers and were prospec-
tively entered into a multicenter cardiac CCTA registry.
The CCTA patients with a history of CABG and coronary
and graft CCTA data were selected for study analysis. The
study was approved by the Human Research Ethics Board at
each participating center, and all patients provided written
informed consent.
Clinical predictors. Modified additive and logistical Eu-
ropean Systems for Cardiac Operative Risk Evaluation
(EuroSCORE) were used. Acute pre-operative markers
of operative and anesthetic risk were not consistently
available (such as pre-operative state, acute endocarditis,
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November 29, 2011:2389–95 Prognostic Utility of CCTA in CABG Patientsneurological dysfunction, pulmonary hypertension, ven-
tricular septal rupture, or additional surgery other than
CABG) and therefore were omitted. With the additive
EuroSCORE, patients were categorized as low (0 to 2),
intermediate (2 to 5), or high risk (5); and for the
ogistic EuroSCORE, patients were categorized as low (0
o 3), intermediate (3 to 10), high (10 to 20), and
ery high risk (20) (7–9).
CTAmeasures (coronary artery disease severity and left
entricular ejection fraction). Native coronary and bypass
raft CCTA image acquisition and interpretation were
erformed with single or dual source 64-slice computed
omography scanners. Coronary and graft diameter stenoses
ere graded with a 4-point score (normal, mild [50%],
oderate [50% to 69%], severe [70%]).
Patients were categorized as having 1, 2, or 3 coronary
rtery disease (CAD) according to the occurrence of
evere disease (70%) in the right coronary, left anterior
escending, and left circumflex territories. Left main
isease was classified as 2-vessel disease for patients with
right dominant circulation and 3-vessel disease for
hose with a left dominant circulation. Branch vessel
isease was apportioned to the parent artery. Revascular-
zation was classified in terms of the territories supplied
y grafts (right coronary, left anterior descending, or left
ircumflex). Bypass grafts to branch vessels were assigned
o the parent artery. A coronary territory was protected if
he native artery supplying the territory did not have
evere disease or if the territory was supplied by a
onstenotic graft (5).
Two models of CAD severity were assessed: unprotected
oronary territories (UCT), and coronary artery protection
core (CAPS) (5,10). The UCT documented the number of
ascular territories that were at risk, whereas CAPS com-
ined the severity of both native and graft disease (Table 1).
atient follow-up. Patient follow-up was performed by
ach local institution by telephone and/or a national death
egistry. Centers in the United States used the Social
ecurity Death Index (11).
tatistical analysis. The statistical software SAS (version
.2, SAS Institute, Inc., Cary, North Carolina) and PASW
Statistics version 18, SPSS, Chicago, Illinois) were used for
ll statistical analyses, and statistical significance was defined
s p  0.05. Continuous variables were expressed as means
nd SDs, and categorical variables were presented as fre-
uencies with percentages. Wilcoxon rank-sum test was
sed to compare continuous variables, and Fisher exact test
r chi-square test was used for categorical variables. In 29%
f patients, left ventricular ejection fraction data were not
ecorded at CCTA and completed by multiple imputation
rocedures assuming missing at random in accordance with
he registry protocol.
The prognostic value of CAPS was assessed for both
nivariable and multivariable associations with all-cause
ortality. Unadjusted comparisons of all-cause mortality
ere performed on survival analysis log-rank tests. An-ual event rates were calculated
y dividing the Kaplan-Meier
vent rates by mean years of
ollow-up. Risk adjusted analy-
es were performed with Cox
roportional hazard models to
etermine the independent prog-
ostic value of CAPS by control-
ing for clinical predictors (addi-
ive EuroSCORE) and creating
djusted survival curves. Model
verfitting was considered, and
he proportional hazards assump-
ion was met. The incremental
alue of CAPS was calculated by
efining the clinical predictors
odel followed by the addition
f CAPS. The area under receiver-
perator characteristic curves (95% confidence intervals
CIs]) was compared to evaluate the discrimination ability
f CAPS over clinical predictors (12). The net reclassifica-
ion improvement (NRI) assessed the improvement of
eclassification with CAPS (13). For calculating the NRI,
escaled individual predicted risks from models with and
ithout CAPS were compared with established Euro-
COREs risk thresholds (7,14,15).
esults
linical characteristics. From the 10,628 patients under-
oing CCTA, diagnostic data were available for 667 pa-
ients with previous CABG surgery. Follow-up was com-
lete on 657 patients (98.5%). The mean follow-up period
as 20 10 months (Table 2). The majority of patients had
oderate- to high-risk EuroSCOREs (Table 3).
linical characteristics associated with mortality. At
ollow-up, all-cause mortality was observed in 44 patients
6.7%) with an annualized mortality rate of 3.8%. Death
ccurred in 35 of the 322 patients (10.9%) with triple-vessel
AD, compared with 3 (1.9%) of 160 patients with single-
essel CAD (Table 4). Patients with all 3 coronary territories
rotected had a crude mortality rate of 3.9%. In contrast,
CAPS Scoring SystemTable 1 CAPS Scoring System
Extent of Native CAD
and Degree of Revascularization CAPS
Single-vessel disease  1 protected territory 1
2-vessel disease  2 protected territories 2
2-vessel disease  1 protected territory 3
2-vessel disease  0 protected territory 4
3-vessel disease  3 protected territories 5
3-vessel disease  2 protected territories 6
3-vessel disease  1 protected territory 7
3-vessel disease  0 protected territory 8
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CAPS  coronary artery
protection score
CCTA  coronary
computed tomography
angiography
CI  confidence interval
EuroSCORE  European
Systems for Cardiac
Operative Risk Evaluation
NRI  net reclassification
improvement
UCT  unprotected
coronary territoryCAD  coronary artery disease; CAPS  coronary artery protection score.
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ries experienced a crude mortality rate of 17.4%.
In the univariable Cox proportional hazard models,
increased hazard ratios for death were associated with
advanced age, left ventricular ejection fraction, creatinine,
severity of native vessel disease, UCT, and CAPS (Tables 4
and 5). Both the additive and logistic EuroSCOREs were
predictive of all-cause mortality (Table 5).
Cox models of risk-adjusted outcomes. The Euro-
SCORE was used to determine the incremental value of
CCTA. In multivariate analyses with the EuroSCORE,
UCT (p 0.004) and CAPS (p 0.001) were independent
predictors of all-cause mortality (Fig. 1, Table 6).
Clinical Characteristics (N  657)Table 2 Clinical Characteristics (N  657)
Age, yrs 68 (61–75)
Male 76.6%
Diabetes 34.1%
Hypertension 76.1%
Family history of coronary artery disease 51.9%
Hyperlipidemia 90.9%
History of smoking 48.9%
History of PVD/CVD 41.2%
Creatinine (mol/l) 83 50
Prior MI 45.2%
LVEF 62.0 (50–70)
BMI 30 kg/m2 35.2%
Chest pain 74.4%
Dyspnoea 57.1%
Values are median (25th to 75th percentile), %, or mean  SD. Symptoms were not recorded in
29% of individuals; percentages represent the frequency of symptoms in those with available data.
BMI  body mass index; CVD  cerebrovascular disease; LVEF  left ventricular ejection
raction; MI  myocardial infarction; PVD  peripheral vascular disease.
Univariable Analysis: Clinical CharacteristicsTable 4 Univariable Analysis: Clinical Chara
Variables
Alive
(n  613
Age, yrs 68.0 (61, 7
Male 468 (76.3
Diabetes 205 (33.6
Hypertension 465 (75.9
Family history of coronary artery disease 320 (52.2
Hyperlipidemia 557 (90.9
History of smoking 294 (48.0
History of PVD/CVD 250 (40.8
Creatinine mol/l 81.1 51.
BMI 30 kg/m2 219 (35.7
Prior MI 272 (44.4
LVEF (10% decrease) 59.7 14.
Additive EuroSCORE
Low 185 (29.9
Intermediate 105 (17.1
High 325 (53.0
Logistic EuroSCORE
Low 60 (9.8%
Intermediate 310 (50.6
High 190 (31.0
Severe 53 (8.6%Values are median (25th, 75th percentile), n (%), or mean  SD.
Abbreviations as in Table 2.Receiver-operator characteristic curves were created for
the additive EuroSCORE, UCT, and CAPS. Area under
the curve was 0.64 (95% CI: 0.56 to 0.71) for additive
EuroSCORE; 0.68 (95% CI: 0.60 to 0.76) for UCT 
additive EuroSCORE (p  0.08); and 0.75 (95% CI: 0.68
to 0.81) for CAPS  additive EuroSCORE (p  0.001)
Fig. 2, Table 6). For this reason, CAPS was used in the
RI calculation. The NRI was performed and demon-
trated that, after clinical risk stratification with additive
uroSCORE, CAPS was able to reclassify 27.2% (p 
.003) of patients (Table 7).
Clinical Variables (N  657)Table 3 Clinical Variables (N  657)
Additive EuroSCORE
Low 188 (28.6)
Moderate 113 (17.2)
High 356 (54.2)
Logistic EuroSCORE
Low 60 (9.1)
Moderate 329 (50.1)
High 207 (31.5)
Severe 61 (9.3)
Grafts to LAD 584 (88.9)
Grafts to LCx 375 (57.1)
Grafts to RCA 408 (62.1)
Left internal mammary artery 485 (73.8)
Other arterial graft 97 (14.6)
Saphenous vein graft 427 (65.0)
Total contrast volume 116 20
Effective dose (mSv) 19.9 8.5
Values are n (%) or mean  SD.
EuroSCORE  European Systems for Cardiac Operative Risk Evaluation; LAD  left anterior
escending artery; LCx  left circumflex artery; RCA  right coronary artery.
tics
All Death
(n  44)
Hazard Ratio
(95% CI) p Value
71.0 (65, 77) 1.04 (1.01–1.08) 0.008
35 (79.5%) 1.20 (0.58–2.50) 0.622
19 (43.2%) 1.49 (0.82–2.70) 0.193
35 (79.5%) 1.23 (0.59–2.55) 0.585
21 (47.7) 0.85 (0.47–1.54) 0.590
40 (91.0%) 1.14 (0.41–3.18) 0.809
27 (61.4%) 1.71 (0.93–3.13) 0.085
21 (47.7%) 1.52 (0.84–2.77) 0.171
114.0 104.8 1.01 (1.00–1.01) 0.001
13 (29.5%) 0.77 (0.41–1.48) 0.438
25 (56.8%) 1.52 (0.84–2.75) 0.168
51.6 20.1% 1.39 (1.17–1.66) 0.001
1.83 (1.21–2.78) 0.004
5 (11.4%)
8 (18.2%)
31 (70.5%)
1.91 (1.32–2.76) 0.001
0
19 (43.2%)
17 (36.8%)
8 (18.2%)cteris
)
5)
%)
%)
%)
%)
%)
%)
%)
4
%)
%)
6%
%)
%)
%)
)
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)
0
t
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c
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w
w
d
CAPS  coronary artery protection score; CCTA  coronary computed tomography angiography;
CI  confidence interval.
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Our analysis demonstrates the usefulness of CCTA to
determine prognosis in the CABG population. The CAPS,
as assessed by CCTA, is incremental to clinical predictors.
The study extends our current understanding of the role of
CCTA and highlights the utility of this technique in the
CABG population.
We also assessed the prognostic utility of UCT and
determined that it did have incremental value over the
EuroSCORE in predicting all-cause mortality (p 
.004) (10). The UCT, however, appeared less predictive
han CAPS. It should be noted, however, that in earlier
escriptions of UCT different outcomes (all-cause mor-
ality vs. nonfatal MI and cardiac death) were used (10).
To understand the value of CAPS, the NRI was
alculated. The NRI demonstrated that, after clinical
valuation, CAPS was able to appropriately reclassify
7.2% of patients.
Overall, the annualized mortality in the study cohort
as 3.8%. Higher levels of annualized mortality rates
ere seen with accumulating severity of native vessel
isease and CAPS score (Fig. 1). The use of CAPS as a
ival for coronary artery protection score (CAPS) (CAPS 1 to 8).Figure 1 Risk-Adjusted Survival Curve for CAPS
Risk-adjusted (for additive European Systems for Cardiac Operative Risk Evaluation) surv
Numbers of patients at risk depicted at 6 monthly intervals.Univariable Analysis: CCTA VariablesTable 5 Univariable Analysis: CCTA Variables
Variables
Alive
(n  613)
All Death
(n  44)
Hazard Ratio
(95% CI) p Value
Native vessel disease 2.63 (1.55–4.46) 0.001
1 157 (25.6%) 3 (6.8%)
2 169 (27.6%) 6 (13.6%)
3 287 (46.8%) 35 (79.5%)
Unprotected territory 1.73 (1.27–2.36) 0.001
0 269 (43.9%) 11 (25.0%)
1 215 (35.1%) 16 (36.4%)
2 110 (18.0%) 13 (29.5%)
3 19 (3.0%) 4 (9.0%)
CAPS 1.40 (1.20–1.63) 0.001
1 157 (25.6%) 3 (6.8%)
2 75 (12.2%) 1 (2.3%)
3 67 (10.9%) 3 (6.8%)
4 27 (4.4%) 2 (4.5%)
5 75 (12.2%) 7 (15.9%)
6 110 (17.9%) 13 (29.5%)
7 83 (13.5%) 11 (25%)
8 19 (3.1%) 4 (9.1%)
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important differences in prognosis between different an-
atomical subgroups and emphasizes that prognosis in
Figure 2 Receiver-Operator Characteristic Curves for Multivaria
Additive European Systems for Cardiac Operative Risk Evaluation  coronary artery pr
versus Additive European Systems for Cardiac Operative Risk Evaluation (blue line) 0.
Cox Models of CCTA MeasuresTable 6 Cox Models of CCTA Measures
Models
Hazard Ratio
(95% CI) p Value
Global Chi-Square
Statistic
Clinical variable 2.23 (1.45–3.45) 0.001
Additive EuroSCORE
Clinical  CCTA data
Additive EuroSCORE 2.04 (1.31–.16) 0.002
UCT 1.35 (0.98–1.84) 0.004 21.5
0 1.00 —
1 1.86 (0.86–4.01) 0.116
2 2.63 (1.17–5.92) 0.020
3 3.95 (1.25–12.50) 0.020
Clinical  CCTA data
Additive EuroSCORE 2.05 (1.33–3.15) 0.001
CAPS 1.35 (1.17–1.56) 0.001 30.5
1 1.00 —
2 0.74 (0.08–7.16) 0.797
3 3.11 (0.63–15.45) 0.166
4 4.46 (0.74–26.77) 0.102
5 5.33 (1.37–20.82) 0.016
6 6.26 (1.78–22.0) 0.004
7 6.21 (1.73–22.32) 0.005
8 8.76 (1.96–39.20) 0.005
Model fitting reported by global chi-square statistic.
UCT  unprotected coronary territory; other abbreviations as in Table 3 and 4.CABG patients does vary. Such results suggest that
certain populations of CABG patients might require
closer clinical surveillance.
Study limitations. Because cardiac death was not available
at all sites, all-cause mortality was used as the outcome
variable. Although the authors recognize that noncardiac
deaths might have been included in the analysis, 87% of all
CABG patient deaths are cardiac (16). The time interval
between CABG surgery and CCTA was not available and
therefore could not be factored into the analysis. Many of
the pre-operative findings and markers of anesthetic risk
were absent; therefore, our modified EuroSCORE calcula-
tion might have under-estimated its true prognostic value.
The registry could not distinguish between the various
grafts used; therefore, we were unable to examine the
influence of different arterial and venous grafts on prognosis.
Not all CCTA studies will be diagnostic in CABG patients.
Because the database did not identify nonevaluable CCTA
studies, the results of this study should only apply to
diagnostic CCTA studies. The mean radiation exposure was
nearly 20 mSv; however, recent technological advances have
reduced radiation exposure significantly, and therefore it is
unlikely this value represents current CCTA practice.
Conclusions
This study suggests that CCTA has independent and
incremental prognostic value in CABG patients in predict-
odels
n score (red line) area under the curve 0.75 (95% confidence interval: 0.68 to 0.81)
% confidence interval: 0.56 to 0.71) (global chi-square  30.5, p  0.001).te M
otectio
64 (95
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November 29, 2011:2389–95 Prognostic Utility of CCTA in CABG Patientsing all-cause mortality. Patients with a low CAPS have
much better outcomes than those with a high CAPS score.
Incremental to the clinical predictors, CCTA-derived
CAPS appropriately reclassified 27.2% of patients. Further
studies are required to understand the role of CCTA in
managing patients after CABG.
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